A Perspective on the Medicare Part B Drug Experiment

via Morning Consult

June 7, 2016

By Bert Liang

The Center for Medicare & Medicaid Innovation (CMMI), a part of the Centers for Medicare and Medicaid Services (CMS), recently issued a proposal of a mandatory experiment designed to evaluate mechanisms to reduce expenditures on prescription drugs reimbursed through Medicare Part B. This proposal would dramatically affect all those within the Medicare ecosystem, and has generated significant controversy since its unveiling. With consideration of both points of view, as a former practicing physician and scientist, and having been involved in the healthcare industry for over 20 years including leading teams developing a number of products which have addressed unmet medical needs, the implications of this mandatory “experiment” is deeply concerning, which could have significant implications on patient care.

Read full article >